2511 (2511) Fair Value & Analysis

Healthcare · Market cap HK$1.4B

2 2511 2511 · HK

PriceHK$2.70

Fair ValueHK$0.4900

Upside-81.9%

Quality37/100

Watch 2511 for free — get notified when fair value or trend changes. Watch for free

Evidence: Low Range HK$0.3200 – HK$0.6200

Fair value as of: Jul 2, 2026

From 1 valuation models · updated today

Share price −13.2% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$1.90 – HK$4.53 · fair‑value band HK$0.3200 – HK$0.6200 · the HK$2.70 price screens above the HK$0.4900 fair value. As of Jul 2, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

2511 (2511) currently trades at HK$2.70, while our model-based Fair Value estimate is HK$0.4900 — implying the stock looks roughly 81.9% overvalued today. We read business quality at 37/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

It earns a return on equity of -58.9%. The balance sheet holds a net cash position of HK$106M. Fundamentals as of Jul 2, 2026

Key figures & financial health

Return on equity -58.9%

Free cash flow −HK$167M FY2026

EPS (TTM) HK$-0.2700

Net cash HK$106M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 2, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

2511 reported revenue of HK$0 in FY2026 versus HK$0 in FY2022. Reported net income was −HK$239M in FY2026.

Revenue

FY22 HK$0

FY23 HK$0

FY24 HK$0

FY25 HK$0

FY26 HK$0

Net income

FY22 −HK$221M

FY23 −HK$190M

FY24 −HK$1.0B

FY25 −HK$382K

FY26 −HK$239M

Is 2511 fairly valued? → Check now

Similar stocks

6 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 2, 2026).

Stock	Price	Fair Value	vs Fair Value
Vertex Pharmaceuticals Incorporated VRTX	7,746 MXN	5,617 MXN	-27%
Regeneron Pharmaceuticals, Inc REGN	$635.45	$547.01	-14%
UCB SA UCB	€247.60	€180.06	-27%
argenx SE ARGNF	$900.00	$382.64	-57%
Alnylam Pharmaceuticals, Inc ALNY	$286.41	$106.81	-63%
Samsung Biologics Co 207940	1,000,000 KRW	1,091,384 KRW	+9%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 2511 (2511) undervalued?

As of Jul 2, 2026, our model estimates a fair value of HK$0.4900 versus a price of HK$2.70 — about −82% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 2511?

Our model-based fair value for 2511 is HK$0.4900 (as of Jul 2, 2026), built from audited fundamentals. The current price is HK$2.70.

What is the quality score of 2511?

2511 has a Quality Score of 37/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the net profit margin of 2511?

The net profit margin of 2511 is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.